GlassScriptPhysician profile
Ulises Barroso
NPI 1669831855
$168.92
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $169.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $74.98 | 2019 | |
| Sanofi-Aventis U.S. LLC | $31.08 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $18.18 | 2019 | |
| Pfizer Pharmaceuticals LLC | $15.80 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.67 | 2019 | |
| Abbvie INC. | $14.21 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ulises Barroso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.